Beta blockers for preventing stroke recurrence

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  De Lima, Luiz Gustavo ^a   Soares, Bernardo ^a   Saconato, Humberto ^b   Da Silva, Edina M K ^a   Atallah, Álvaro N ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CAUSE OF DEATH; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; RECURRENT DISEASE; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 70049105127     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007890     Document Type: Review

References (17)

1. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003;362:1527-1535
2. Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke - evidence of the need for a standard definition. Stroke 2004;35:1925-1929
3. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
4. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): amulticentre randomized controlled trial. Lancet 2005;366:895-906. (Pubitemid 41265663)
5. Dhakam Z, McEniery CM, Yasmin C, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. American Journal of Hypertension 2006;19(2):214-219 (Pubitemid 43350177)
6. The DUTCHTIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543-548
7. Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, et al.Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997;12:2557-2562
8. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al.Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998;29(12):2491-2500 (Pubitemid 28543996)
9. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-2031 (Pubitemid 38781102)
10. Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-1518
11. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553 (Pubitemid 41540112)
12. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008;117(20):2706-2715
13. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358(9287):1033-1041 (Pubitemid 32925123)
14. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
15. Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost effectiveness analysis. Clinical Therapy 2000;22:363-370 (Pubitemid 30213143)
16. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurology 2007;6:182-187 (Pubitemid 46097543)
17. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al.Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. [Art. No.: CD002003. DOI: 10.1002/14651858.CD002003.pub2]